<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35052628</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-3921</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>06</Day></PubDate></JournalIssue><Title>Antioxidants (Basel, Switzerland)</Title><ISOAbbreviation>Antioxidants (Basel)</ISOAbbreviation></Journal><ArticleTitle>Potential Therapeutic Use of the Rosemary Diterpene Carnosic Acid for Alzheimer's Disease, Parkinson's Disease, and Long-COVID through NRF2 Activation to Counteract the NLRP3 Inflammasome.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">124</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/antiox11010124</ELocationID><Abstract><AbstractText>Rosemary (<i>Rosmarinus officinalis</i> [family Lamiaceae]), an herb of economic and gustatory repute, is employed in traditional medicines in many countries. Rosemary contains carnosic acid (CA) and carnosol (CS), abietane-type phenolic diterpenes, which account for most of its biological and pharmacological actions, although claims have also been made for contributions of another constituent, rosmarinic acid. This review focuses on the potential applications of CA and CS for Alzheimer's disease (AD), Parkinson's disease (PD), and coronavirus disease 2019 (COVID-19), in part via inhibition of the NLRP3 inflammasome. CA exerts antioxidant, anti-inflammatory, and neuroprotective effects via phase 2 enzyme induction initiated by activation of the KEAP1/NRF2 transcriptional pathway, which in turn attenuates NLRP3 activation. In addition, we propose that CA-related compounds may serve as therapeutics against the brain-related after-effects of SARS-CoV-2 infection, termed "long-COVID." One factor that contributes to COVID-19 is cytokine storm emanating from macrophages as a result of unregulated inflammation in and around lung epithelial and endovascular cells. Additionally, neurological aftereffects such as anxiety and "brain fog" are becoming a major issue for both the pandemic and post-pandemic period. Many reports hold that unregulated NLRP3 inflammasome activation may potentially contribute to the severity of COVID-19 and its aftermath. It is therefore possible that suppression of NLRP3 inflammasome activity may prove efficacious against both acute lung disease and chronic neurological after-effects. Because CA has been shown to not only act systemically but also to penetrate the blood-brain barrier and reach the brain parenchyma to exert neuroprotective effects, we discuss the evidence that CA or rosemary extracts containing CA may represent an effective countermeasure against both acute and chronic pathological events initiated by SARS-CoV-2 infection as well as other chronic neurodegenerative diseases including AD and PD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Satoh</LastName><ForeName>Takumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anti-Aging Food Research, School of Bioscience and Biotechnology, Tokyo University of Technology, 1404-1 Katakura, Hachioji 192-0982, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trudler</LastName><ForeName>Dorit</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Departments of Molecular Medicine and Neuroscience and Neurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Chang-Ki</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Departments of Molecular Medicine and Neuroscience and Neurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>Stuart A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Departments of Molecular Medicine and Neuroscience and Neurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, CA 92037, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences, University of California San Diego School of Medicine, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 AG071734</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG078756</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056259</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057409, R01 AG056259, R01 DA048882, R01 NS086890 and DP1 DA041722</GrantID><Agency>NIH grants</Agency><Country/></Grant><Grant><GrantID>DISC2 COVID19-11811, and a COVID-19 award from Fast Grants</GrantID><Agency>California Institute for Regenerative Medicine (CIRM) grant</Agency><Country/></Grant><Grant><GrantID>R01 DA048882</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG057409</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Antioxidants (Basel)</MedlineTA><NlmUniqueID>101668981</NlmUniqueID><ISSNLinking>2076-3921</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">NLRP3 inflammasome</Keyword><Keyword MajorTopicYN="N">NRF2 activators</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">carnosic acid</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">microglia</Keyword><Keyword MajorTopicYN="N">rosemary</Keyword></KeywordList><CoiStatement>The authors disclose that T.S. and S.A.L. are patent holders for the use of carnosic acid congeners for degenerative diseases. Scripps Research, the home institute of S.A.L., has also filed for patent protection for the composition of matter and use of carnosic acid derivatives in a variety of neurodegenerative disorders and other conditions. The other authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>21</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35052628</ArticleId><ArticleId IdType="pmc">PMC8772720</ArticleId><ArticleId IdType="doi">10.3390/antiox11010124</ArticleId><ArticleId IdType="pii">antiox11010124</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nieto G., Ros G., Castillo J. Antioxidant and antimicrobial properties of rosemary (Rosmarinus officinalis, L.): A review. Medicines. 2018;5:98. doi: 10.3390/medicines5030098.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicines5030098</ArticleId><ArticleId IdType="pmc">PMC6165352</ArticleId><ArticleId IdType="pubmed">30181448</ArticleId></ArticleIdList></Reference><Reference><Citation>De Oliveira J.R., Camargo S.E.A., de Oliveira L.D. Rosmarinus officinalis L.(rosemary) as therapeutic and prophylactic agent. J. Biomed. Sci. 2019;26:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6325740</ArticleId><ArticleId IdType="pubmed">30621719</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore J., Yousef M., Tsiani E. Anticancer effects of rosemary (Rosmarinus officinalis L.) extract and rosemary extract polyphenols. Nutrients. 2016;8:731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5133115</ArticleId><ArticleId IdType="pubmed">27869665</ArticleId></ArticleIdList></Reference><Reference><Citation>Generally Recognized as Safe (GRAS) in USA.  [(accessed on 19 November 2021)]; Available online:  https://www.fda.gov/food/food-ingredients-packaging/generally-recognized-safe-gras.</Citation></Reference><Reference><Citation>5. Current EU Approval and Their E Number in EU.  [(accessed on 19 November 2021)].  Available online:  https://ec.europa.eu/food/safety/food-improvement-agents/additives/database_en.</Citation></Reference><Reference><Citation>Approved Food Additives by Ministry of Health, Labor and Welfare of Japan.  [(accessed on 19 November 2021)].  Available online:  https://www.ffcr.or.jp/tenka/list/post-12.html?OpenDocument.</Citation></Reference><Reference><Citation>Andrade J.M., Faustino C., Garcia C., Ladeiras D., Reis C.P., Rijo P. Rosmarinus officinalis L.: An update review of its phytochemistry and biological activity. Future Sci. OA. 2018;4:FSO283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5905578</ArticleId><ArticleId IdType="pubmed">29682318</ArticleId></ArticleIdList></Reference><Reference><Citation>De Oliveira M.R. The dietary components carnosic acid and carnosol as neuroprotective agents: A mechanistic view. Mol. Neurobiol. 2016;53:6155&#x2013;6168. doi: 10.1007/s12035-015-9519-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9519-1</ArticleId><ArticleId IdType="pubmed">26553346</ArticleId></ArticleIdList></Reference><Reference><Citation>Loussouarn M., Krieger-Liszkay A., Svilar L., Bily A., Birti&#x107; S., Havaux M. Carnosic acid and carnosol, two major antioxidants of rosemary, act through different mechanisms. Plant Physiol. 2017;175:1381&#x2013;1394. doi: 10.1104/pp.17.01183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1104/pp.17.01183</ArticleId><ArticleId IdType="pmc">PMC5664485</ArticleId><ArticleId IdType="pubmed">28916593</ArticleId></ArticleIdList></Reference><Reference><Citation>Chae I.G., Yu M.H., Im N.K., Jung Y.T., Lee J., Chun K.S., Lee I.S. Effect of Rosmarinus officinalis L. on MMP-9, MCP-1 levels, and cell migration in RAW 264.7 and smooth muscle cells. J. Med. Food. 2012;15:879&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3466913</ArticleId><ArticleId IdType="pubmed">22985398</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo C.F., Su J.D., Chiu C.H., Peng C.C., Chang C.H., Sung T.Y., Huang S.H., Lee W.C., Chyau C.C. Anti-inflammatory effects of supercritical carbon dioxide extract and its isolated carnosic acid from Rosmarinus officinalis leaves. J. Agric. Food Chem. 2011;59:3674&#x2013;3685. doi: 10.1021/jf104837w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jf104837w</ArticleId><ArticleId IdType="pubmed">21375325</ArticleId></ArticleIdList></Reference><Reference><Citation>Est&#xe9;vez M., Ventanas S., Ram&#xed;rez R., Cava R. Analysis of volatiles in porcine liver p&#xe2;t&#xe9;s with added sage and rosemary essential oils by using SPME-GC-MS. J. Agric. Food Chem. 2004;52:5168&#x2013;5174. doi: 10.1021/jf0496705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jf0496705</ArticleId><ArticleId IdType="pubmed">15291492</ArticleId></ArticleIdList></Reference><Reference><Citation>Foresti R., Bains S.K., Pitchumony T.S., Br&#xe1;s L.E.D.C., Drago F., Dubois-Rand&#xe9; J.-L., Bucolo C., Motterlini R. Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells. Pharmacol. Res. 2013;76:132&#x2013;148. doi: 10.1016/j.phrs.2013.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2013.07.010</ArticleId><ArticleId IdType="pubmed">23942037</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q., Shen Z., Yu H., Lu G., Yu Y., Liu X., Zheng P. Carnosic acid protects against acetaminophen-induced hepatotoxicity by potentiating Nrf2-mediated antioxidant capacity in mice. Korean J. Physiol. Pharmacol. 2016;20:15&#x2013;23. doi: 10.4196/kjpp.2016.20.1.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.4196/kjpp.2016.20.1.15</ArticleId><ArticleId IdType="pmc">PMC4722187</ArticleId><ArticleId IdType="pubmed">26807019</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanagitai M., Itoh S., Kitagawa T., Takenouchi T., Kitani H., Satoh T. Carnosic acid, a pro-electrophilic compound, inhibits LPS-induced activation of microglia. Biochem. Biophys. Res. Commun. 2012;418:22&#x2013;26. doi: 10.1016/j.bbrc.2011.12.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2011.12.087</ArticleId><ArticleId IdType="pubmed">22214931</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadad N., Levy R. Combination of EPA with carotenoids and polyphenol synergistically attenuated the transformation of microglia to M1 phenotype via inhibition of NF-&#x3ba;B. Neuromol. Med. 2017;19:436&#x2013;451. doi: 10.1007/s12017-017-8459-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-017-8459-5</ArticleId><ArticleId IdType="pubmed">28779377</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Zhao L., Han J.J., Zhang F., Liu S., Zhu L., Wang Z.Z., Zhang G.X., Zhang Y. Carnosol modulates Th17 cell differentiation and microglial switch in experimental autoimmune encephalomyelitis. Front. Immunol. 2018;9:1807. doi: 10.3389/fimmu.2018.01807.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01807</ArticleId><ArticleId IdType="pmc">PMC6100297</ArticleId><ArticleId IdType="pubmed">30150982</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen D.V., Hanson J.E., Sheng M. Microglia in Alzheimer&#x2019;s disease. J. Cell Biol. 2018;217:459&#x2013;472. doi: 10.1083/jcb.201709069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201709069</ArticleId><ArticleId IdType="pmc">PMC5800817</ArticleId><ArticleId IdType="pubmed">29196460</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M.S. Microglia in Parkinson&#x2019;s Disease. Adv. Exp. Med. Biol. 2019;1175:335&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">31583594</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., He D., Bai Y. Microglia-Mediated Inflammation and Neurodegenerative Disease. Mol. Neurobiol. 2015;53:6709&#x2013;6715. doi: 10.1007/s12035-015-9593-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9593-4</ArticleId><ArticleId IdType="pubmed">26659872</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K., Sun Q., Zhong X., Zeng M., Zeng H., Shi X., Li Z., Wang Y., Zhao Q., Shao F., et al. Structural mechanism for GSDMD targeting by autoprocessed caspases in pyroptosis. Cell. 2020;180:941&#x2013;955.e20. doi: 10.1016/j.cell.2020.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.002</ArticleId><ArticleId IdType="pubmed">32109412</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Ma W., Gao W., Xing Y., Chen L., Xia Z., Zhang Z., Dai Z. Propofol directly induces caspase-1-dependent macrophage pyroptosis through the NLRP3-ASC inflammasome. Cell Death Dis. 2019;10:542. doi: 10.1038/s41419-019-1761-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-019-1761-4</ArticleId><ArticleId IdType="pmc">PMC6637184</ArticleId><ArticleId IdType="pubmed">31316052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutterwala F.S., Haasken S., Cassel S.L. Mechanism of NLRP3 inflammasome activation. Ann. N.Y. Acad. Sci. 2014;1319:82&#x2013;95. doi: 10.1111/nyas.12458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nyas.12458</ArticleId><ArticleId IdType="pmc">PMC4074217</ArticleId><ArticleId IdType="pubmed">24840700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley N., Jeltema D., Duan Y., He Y. The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. Int. J. Mol. Sci. 2019;20:3328. doi: 10.3390/ijms20133328.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20133328</ArticleId><ArticleId IdType="pmc">PMC6651423</ArticleId><ArticleId IdType="pubmed">31284572</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q., Scott M.J. Caspase-1 as a multifunctional inflammatory mediator: Noncytokine maturation roles. J. Leukoc. Biol. 2016;100:961&#x2013;967. doi: 10.1189/jlb.3MR0516-224R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.3MR0516-224R</ArticleId><ArticleId IdType="pmc">PMC6608062</ArticleId><ArticleId IdType="pubmed">27450556</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou R., Yazdi A.S., Menu P., Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469:221&#x2013;225. doi: 10.1038/nature09663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09663</ArticleId><ArticleId IdType="pubmed">21124315</ArticleId></ArticleIdList></Reference><Reference><Citation>Minutoli L., Puzzolo D., Rinaldi M., Irrera N., Marini H.R., Arcoraci V., Bitto A., Crea G., Pisani A., Squadrito F., et al. ROS-mediated NLRP3 inflammasome activation in brain, heart, kidney, and testis ischemia/reperfusion injury. Oxidative Med. Cell. Longev. 2016;2016:2183026. doi: 10.1155/2016/2183026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/2183026</ArticleId><ArticleId IdType="pmc">PMC4835650</ArticleId><ArticleId IdType="pubmed">27127546</ArticleId></ArticleIdList></Reference><Reference><Citation>Trudler D., Nazor K.L., Eisele Y.S., Grabauskas T., Dolatabadi N., Parker J., Sultan A., Zhong Z., Goodwin M.S., Levites Y., et al. Soluble &#x3b1;-synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia. Proc. Natl. Acad. Sci. USA. 2021;118:e2025847118. doi: 10.1073/pnas.2025847118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2025847118</ArticleId><ArticleId IdType="pmc">PMC8054017</ArticleId><ArticleId IdType="pubmed">33833060</ArticleId></ArticleIdList></Reference><Reference><Citation>Ising C., Venegas C., Zhang S., Scheiblich H., Schmidt S.V., Vieira-Saecker A., Schwartz S., Albasset S., McManus R.M., Tejera D., et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575:669&#x2013;673. doi: 10.1038/s41586-019-1769-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-019-1769-z</ArticleId><ArticleId IdType="pmc">PMC7324015</ArticleId><ArticleId IdType="pubmed">31748742</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Dai Y., Li Q., Chen C., Chen H., Song Y., Hua F., Zhang Z. &#x3b2;-Amyloid activates NLRP3 inflammasome via TLR4 in mouse microglia. Neurosci. Lett. 2020;736:135279. doi: 10.1016/j.neulet.2020.135279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2020.135279</ArticleId><ArticleId IdType="pubmed">32726591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E., Hwang I., Park S., Hong S., Hwang B., Cho Y., Son J., Yu J.-W. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ. 2019;26:213&#x2013;228. doi: 10.1038/s41418-018-0124-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-018-0124-5</ArticleId><ArticleId IdType="pmc">PMC6329843</ArticleId><ArticleId IdType="pubmed">29786072</ArticleId></ArticleIdList></Reference><Reference><Citation>Holbrook J.A., Jarosz-Griffiths H.H., Caseley E., Lara-Reyna S., Poulter J.A., Williams-Gray C.H., Peckham D., McDermott M.F. Neurodegenerative disease and the NLRP3 inflammasome. Front. Pharmacol. 2021;12:643254. doi: 10.3389/fphar.2021.643254.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.643254</ArticleId><ArticleId IdType="pmc">PMC7987926</ArticleId><ArticleId IdType="pubmed">33776778</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu A.G., Zhou X.G., Qiao G., Yu L., Tang Y., Yan L., Qiu W.Q., Pan R., Yu C.L., Law B.Y., et al. Targeting microglial autophagic degradation in NLRP3 inflammasome-mediated neurodegenerative diseases. Ageing Res. Rev. 2021;65:101202. doi: 10.1016/j.arr.2020.101202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2020.101202</ArticleId><ArticleId IdType="pubmed">33161129</ArticleId></ArticleIdList></Reference><Reference><Citation>Itoh K., Igarashi K., Hayashi N., Nishizawa M., Yamamoto M. Cloning and characterization of a novel erythroid cell-derived CNC family transcription factor heterodimerizing with the small Maf family proteins. Mol. Cell. Biol. 1995;15:4184&#x2013;4193. doi: 10.1128/MCB.15.8.4184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.15.8.4184</ArticleId><ArticleId IdType="pmc">PMC230657</ArticleId><ArticleId IdType="pubmed">7623813</ArticleId></ArticleIdList></Reference><Reference><Citation>Tebay L.E., Robertson H., Durant S.T., Vitale S.R., Penning T.M., Dinkova-Kostova A.T., Hayes J.D. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues, and energy status and the pathways through which it attenuates degenerative disease. Free Radic. Biol. Med. 2015;88 Pt B:108&#x2013;146. doi: 10.1016/j.freeradbiomed.2015.06.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.06.021</ArticleId><ArticleId IdType="pmc">PMC4659505</ArticleId><ArticleId IdType="pubmed">26122708</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T., Lipton S.A. Redox regulation of neuronal survival mediated by electrophilic compounds. Trends Neurosci. 2007;30:37&#x2013;45. doi: 10.1016/j.tins.2006.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2006.11.004</ArticleId><ArticleId IdType="pubmed">17137643</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T., McKercher S.R., Lipton S.A. Nrf2/ARE-mediated antioxidant actions of pro-electrophilic drugs. Free Radic. Biol Med. 2013;65:645&#x2013;657. doi: 10.1016/j.freeradbiomed.2013.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.07.022</ArticleId><ArticleId IdType="pmc">PMC3859717</ArticleId><ArticleId IdType="pubmed">23892355</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T., Lipton S. Recent advances in understanding NRF2 as a druggable target: Development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate. F1000Research. 2017;6:2138. doi: 10.12688/f1000research.12111.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.12111.1</ArticleId><ArticleId IdType="pmc">PMC5730864</ArticleId><ArticleId IdType="pubmed">29263788</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T., Okamoto S.I., Cui J., Watanabe Y., Furuta K., Suzuki M., Tohyama K., Lipton S.A. Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic phase II inducers. Proc. Natl. Acad. Sci. USA. 2006;103:768&#x2013;773. doi: 10.1073/pnas.0505723102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0505723102</ArticleId><ArticleId IdType="pmc">PMC1334635</ArticleId><ArticleId IdType="pubmed">16407140</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J.-W., Lee M.-S. Mitochondria and the NLRP3 inflammasome: Physiological and pathological relevance. Arch. Pharm. Res. 2016;39:1503&#x2013;1518. doi: 10.1007/s12272-016-0827-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12272-016-0827-4</ArticleId><ArticleId IdType="pubmed">27600432</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills E.L., Kelly B., O&#x2019;Neill L.A.J. Mitochondria are the powerhouses of immunity. Nat. Immunol. 2017;18:488&#x2013;498. doi: 10.1038/ni.3704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3704</ArticleId><ArticleId IdType="pubmed">28418387</ArticleId></ArticleIdList></Reference><Reference><Citation>Han M., Li S., Li L. Verapamil inhibits early acute liver failure through suppressing the NLRP3 inflammasome pathway. J. Cell. Mol. Med. 2021;25:5963&#x2013;5975. doi: 10.1111/jcmm.16357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.16357</ArticleId><ArticleId IdType="pmc">PMC8256349</ArticleId><ArticleId IdType="pubmed">34031983</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian N., Natarajan K., Clatworthy M.R., Wang Z., Germain R.N. The adaptor MAVS promotes NLRP3 mitochondriallLocalization and inflammasome activation. Cell. 2013;153:348&#x2013;361. doi: 10.1016/j.cell.2013.02.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.02.054</ArticleId><ArticleId IdType="pmc">PMC3632354</ArticleId><ArticleId IdType="pubmed">23582325</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S., Juliana C., Hong S., Datta P., Hwang I., Fernandes-Alnemri T., Yu J.-W., Alnemri E.S. The mitochondrial antiviral protein MAVS associates with NLRP3 and regulates its inflammasome activity. J. Immunol. 2013;191:4358&#x2013;4366. doi: 10.4049/jimmunol.1301170.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1301170</ArticleId><ArticleId IdType="pmc">PMC3848201</ArticleId><ArticleId IdType="pubmed">24048902</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie K., Zhang Y., Wang Y., Meng X., Wang Y., Yu Y., Chen H. Hydrogen attenuates sepsis-associated encephalopathy by NRF2 mediated NLRP3 pathway inactivation. Agents Actions. 2020;69:697&#x2013;710. doi: 10.1007/s00011-020-01347-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-020-01347-9</ArticleId><ArticleId IdType="pubmed">32350570</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L.L., Wu Y.F., Yan F., Li C.C., Dai Z., You Q.D., Jiang Z.Y., Di B. 5-(3,4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson&#x2019;s disease in mice by inhibiting the NLRP3 inflammasome and protects PC12 cells against oxidative stress. Free Radic. Biol. Med. 2019;134:288&#x2013;303.</Citation><ArticleIdList><ArticleId IdType="pubmed">30615919</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagasaki H., Yoshimura T., Aoki N. Real-time monitoring of inflammation status in 3T3-L1 adipocytes possessing a secretory Gaussia luciferase gene under the control of nuclear factor-&#x3ba;B response element. Biochem. Biophys. Res. Commun. 2012;420:623&#x2013;627. doi: 10.1016/j.bbrc.2012.03.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2012.03.049</ArticleId><ArticleId IdType="pubmed">22450310</ArticleId></ArticleIdList></Reference><Reference><Citation>Xian H., Liu Y., Rundberg Nilsson A., Gatchalian R., Crother T.R., Tourtellotte W.G., Zhang Y., Aleman-Muench G.R., Lewis G., Chen W., et al. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation. Immunity. 2021;54:1463&#x2013;1477.e11. doi: 10.1016/j.immuni.2021.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.05.004</ArticleId><ArticleId IdType="pmc">PMC8189765</ArticleId><ArticleId IdType="pubmed">34115964</ArticleId></ArticleIdList></Reference><Reference><Citation>Palladino M.A., Bahjat F.R., Theodorakis E.A., Moldawer L.L. Anti-TNF-&#x3b1; therapies: The next generation. Nat. Rev. Drug Discov. 2003;2:736&#x2013;746. doi: 10.1038/nrd1175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd1175</ArticleId><ArticleId IdType="pubmed">12951580</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaki Y., Tabuchi T., Takahashi T., Kosaka K., Satoh T. Activated glutathione metabolism participates in protective effects of carnosic acid against oxidative stress in neuronal HT22 cells. Planta Medica. 2009;76:683&#x2013;688. doi: 10.1055/s-0029-1240622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0029-1240622</ArticleId><ArticleId IdType="pubmed">19941258</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T., Izumi M., Inukai Y., Tsutsumi Y., Nakayama N., Kosaka K., Shimojo Y., Kitajima C., Itoh K., Yokoi T., et al. Carnosic acid protects neuronal HT22 cells through activation of the antioxidant-responsive element in free carboxylic acid- and catechol hydroxyl moieties-dependent manners. Neurosci. Lett. 2008;434:260&#x2013;265. doi: 10.1016/j.neulet.2008.01.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2008.01.079</ArticleId><ArticleId IdType="pubmed">18329808</ArticleId></ArticleIdList></Reference><Reference><Citation>Tena M.T., Valc&#xe1;rcel M., Hidalgo P.J., Ubera J.L. Supercritical fluid extraction of natural antioxidants from rosemary:&#x2009; comparison with liquid solvent sonication. Anal. Chem. 1997;69:521&#x2013;526. doi: 10.1021/ac960506t.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ac960506t</ArticleId><ArticleId IdType="pubmed">21639201</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T., Stalder R., McKercher S.R., Williamson R.E., Roth G.P., Lipton S.A. Nrf2 and HSF-1 pathway activation via hydroquinone-based proelectrophilic small molecules is regulated by electrochemical oxidation potential. ASN Neuro. 2015;7:1759091415593294. doi: 10.1177/1759091415593294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1759091415593294</ArticleId><ArticleId IdType="pmc">PMC4550314</ArticleId><ArticleId IdType="pubmed">26243592</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T., Saitoh S., Hosaka M., Kosaka K. Simple ortho- and para-hydroquinones as compounds neuroprotective against oxidative stress in a manner associated with specific transcriptional activation. Biochem. Biophys. Res. Commun. 2009;379:537&#x2013;541. doi: 10.1016/j.bbrc.2008.12.106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2008.12.106</ArticleId><ArticleId IdType="pubmed">19118528</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T., Kosaka K., Itoh K., Kobayashi A., Yamamoto M., Shimojo Y., Kitajima C., Cui J., Kamins J., Okamoto S., et al. Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. J. Neurochem. 2008;104:1116&#x2013;1131. doi: 10.1111/j.1471-4159.2007.05039.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.05039.x</ArticleId><ArticleId IdType="pmc">PMC4566957</ArticleId><ArticleId IdType="pubmed">17995931</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachakonda G., Xiong Y., Sekhar K.R., Stamer S.L., Liebler D.C., Freeman M.L. Covalent modification at Cys151 dissociates the electrophile sensor Keap1 from the ubiquitin ligase CUL3. Chem. Res. Toxicol. 2008;21:705&#x2013;710. doi: 10.1021/tx700302s.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/tx700302s</ArticleId><ArticleId IdType="pubmed">18251510</ArticleId></ArticleIdList></Reference><Reference><Citation>Baird L., Yamamoto M. The molecular mechanisms regulating the KEAP1-NRF2 pathway. Mol. Cell. Biol. 2020;40:e00099-20. doi: 10.1128/MCB.00099-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.00099-20</ArticleId><ArticleId IdType="pmc">PMC7296212</ArticleId><ArticleId IdType="pubmed">32284348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopacz A., Kloska D., Forman H.J., Jozkowicz A., Grochot-Przeczek A. Beyond repression of Nrf2: An update on Keap1. Free Radic. Biol. Med. 2020;157:63&#x2013;74. doi: 10.1016/j.freeradbiomed.2020.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2020.03.023</ArticleId><ArticleId IdType="pmc">PMC7732858</ArticleId><ArticleId IdType="pubmed">32234331</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagar S., Noveral S.M., Trudler D., Lopez K.M., McKercher S.R., Han X., Yates J.R., 3rd, Pi&#xf1;a-Crespo J.C., Nakanishi N., Satoh T., et al. MEF2D haploinsufficiency downregulates the NRF2 pathway and renders photoreceptors susceptible to light-induced oxidative stress. Proc. Natl. Acad. Sci. USA. 2017;114:E4048&#x2013;E4056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5441815</ArticleId><ArticleId IdType="pubmed">28461502</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T., Rezaie T., Seki M., Sunico C.R., Tabuchi T., Kitagawa T., Yanagitai M., Senzaki M., Kosegawa C., Taira H., et al. Dual neuroprotective pathways of a pro-electrophilic compound via HSF-1-activated heat-shock proteins and Nrf2-activated phase 2 antioxidant response enzymes. J. Neurochem. 2011;119:569&#x2013;578. doi: 10.1111/j.1471-4159.2011.07449.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07449.x</ArticleId><ArticleId IdType="pmc">PMC4580255</ArticleId><ArticleId IdType="pubmed">21883218</ArticleId></ArticleIdList></Reference><Reference><Citation>Maynard M.E., Underwood E.L., Redell J.B., Zhao J., Kobori N., Hood K.N., Moore A.N., Dash P.K. Carnosic acid improves outcome after repetitive mild traumatic brain injury. J. Neurotrauma. 2019;36:2147&#x2013;2152. doi: 10.1089/neu.2018.6155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2018.6155</ArticleId><ArticleId IdType="pmc">PMC6602106</ArticleId><ArticleId IdType="pubmed">30672378</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaie T., McKercher S.R., Kosaka K., Seki M., Wheeler L., Viswanath V., Chun T., Joshi R., Valencia M., Sasaki S., et al. Protective effect of carnosic acid, a pro-electrophilic compound, in models of oxidative stress and light-induced retinal degeneration. Invest. Ophthalmol. Vis. Sci. 2012;53:7847&#x2013;7854. doi: 10.1167/iovs.12-10793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.12-10793</ArticleId><ArticleId IdType="pmc">PMC3508754</ArticleId><ArticleId IdType="pubmed">23081978</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwager J., Richard N., Fowler A., Seifert N., Raederstorff D. Carnosol and related substances modulate chemokine and cytokine production in macrophages and chondrocytes. Molecules. 2016;21:465. doi: 10.3390/molecules21040465.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules21040465</ArticleId><ArticleId IdType="pmc">PMC6274263</ArticleId><ArticleId IdType="pubmed">27070563</ArticleId></ArticleIdList></Reference><Reference><Citation>Habtemariam S. The Therapeutic Potential of rosemary (Rosmarinus officinalis) diterpenes for Alzheimer&#x2019;s disease. Evid. Based Complement. Altern. Med. 2016;2016:2680409. doi: 10.1155/2016/2680409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/2680409</ArticleId><ArticleId IdType="pmc">PMC4749867</ArticleId><ArticleId IdType="pubmed">26941822</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry N.S.L., Menzies R., Hodgson F., Wedgewood P., Howes M.R., Brooker H.J., Wesnes K.A., Perry E.K. A randomised double-blind placebo-controlled pilot trial of a combined extract of sage, rosemary and melissa, traditional herbal medicines, on the enhancement of memory in normal healthy subjects, including influence of age. Phytomedicine. 2018;39:42&#x2013;48. doi: 10.1016/j.phymed.2017.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phymed.2017.08.015</ArticleId><ArticleId IdType="pubmed">29433682</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipton S.A., Rezaie T., Nutter A., Lopez K.M., Parker J., Kosaka K., Satoh T., McKercher S.R., Masliah E., Nakanishi N. Therapeutic advantage of pro-electrophilic drugs to activate the Nrf2/ARE pathway in Alzheimer&#x2019;s disease models. Cell Death Dis. 2016;7:e2499. doi: 10.1038/cddis.2016.389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2016.389</ArticleId><ArticleId IdType="pmc">PMC5261011</ArticleId><ArticleId IdType="pubmed">27906174</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.-R., Tsai C.-W., Chang S.-W., Lin C.-Y., Huang L.-C. Carnosic acid protects against 6-hydroxydopamine-induced neurotoxicity in in vivo and in vitro model of Parkinson&#x2019;s disease: Involvement of antioxidative enzymes induction. Chem. Interact. 2015;225:40&#x2013;46. doi: 10.1016/j.cbi.2014.11.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cbi.2014.11.011</ArticleId><ArticleId IdType="pubmed">25446857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.J., Kim J.S., Cho H.S., Lee H.J., Kim S.Y., Kim S., Lee S.Y., Chun H.S. Carnosol, a component of rosemary (Rosmarinus officinalis L.) protects nigral dopaminergic neuronal cells. NeuroReport. 2006;17:1729&#x2013;1733.</Citation><ArticleIdList><ArticleId IdType="pubmed">17047462</ArticleId></ArticleIdList></Reference><Reference><Citation>Esteras N., Abramov A.Y. Mitochondrial calcium deregulation in the mechanism of &#x3b2;-amyloid and tau pathology. Cells. 2020;9:2135. doi: 10.3390/cells9092135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9092135</ArticleId><ArticleId IdType="pmc">PMC7564294</ArticleId><ArticleId IdType="pubmed">32967303</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Yu S., Zheng Y., Yang H., Zhang J. Oxidative modification and its implications for the neurodegeneration of Parkinson&#x2019;s disease. Mol. Neurobiol. 2017;54:1404&#x2013;1418. doi: 10.1007/s12035-016-9743-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-9743-3</ArticleId><ArticleId IdType="pubmed">26843115</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez E., Chin T.Y., Chen C.P., Wu T.Y. Management of moderate toa severe Alzheimer&#x2019;s disease: Focus on memantine. Taiwan J. Obstet Gynecol. 2011;50:415&#x2013;423. doi: 10.1016/j.tjog.2011.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tjog.2011.10.004</ArticleId><ArticleId IdType="pubmed">22212311</ArticleId></ArticleIdList></Reference><Reference><Citation>Geldenhuys W.J., Van der Schyf C.J. Rationally designed multi-targeted agents against neurodegenerative diseases. Curr. Med. Chem. 2013;20:1662&#x2013;1672. doi: 10.2174/09298673113209990112.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/09298673113209990112</ArticleId><ArticleId IdType="pubmed">23410161</ArticleId></ArticleIdList></Reference><Reference><Citation>Asselah T., Durantel D., Pasmant E., Lau G., Schinazi R.F. COVID-19: Discovery, diagnostics and drug development. J. Hepatol. 2020;74:168&#x2013;184. doi: 10.1016/j.jhep.2020.09.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2020.09.031</ArticleId><ArticleId IdType="pmc">PMC7543767</ArticleId><ArticleId IdType="pubmed">33038433</ArticleId></ArticleIdList></Reference><Reference><Citation>De Candia P., Prattichizzo F., Garavelli S., Matarese G. T cells: Warriors of SARS-CoV-2 infection. Trends Immunol. 2021;42:18&#x2013;30. doi: 10.1016/j.it.2020.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2020.11.002</ArticleId><ArticleId IdType="pmc">PMC7664351</ArticleId><ArticleId IdType="pubmed">33277181</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrityunjaya M., Pavithra V., Neelam R., Janhavi P., Halami P.M., Ravindra P.V. Immune-boosting, antioxidant and anti-inflammatory food supplements targeting pathogenesis of COVID-19. Front. Immunol. 2020;11:570122. doi: 10.3389/fimmu.2020.570122.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.570122</ArticleId><ArticleId IdType="pmc">PMC7575721</ArticleId><ArticleId IdType="pubmed">33117359</ArticleId></ArticleIdList></Reference><Reference><Citation>Uddin M., Mustafa F., Rizvi T.A., Loney T., Suwaidi H.A., Al-Marzouqi A.H.H., Eldin A.K., Alsabeeha N., Adrian T.E., Stefanini C., et al. SARS-CoV-2/COVID-19: Viral genomics, epidemiology, vaccines, and therapeutic interventions. Viruses. 2020;12:526. doi: 10.3390/v12050526.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12050526</ArticleId><ArticleId IdType="pmc">PMC7290442</ArticleId><ArticleId IdType="pubmed">32397688</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman T., Swartz T.H. Targeting the NLRP3 Inflammasome in severe COVID-19. Front. Immunol. 2020;11:1518. doi: 10.3389/fimmu.2020.01518.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01518</ArticleId><ArticleId IdType="pmc">PMC7324760</ArticleId><ArticleId IdType="pubmed">32655582</ArticleId></ArticleIdList></Reference><Reference><Citation>Toldo S., Bussani R., Nuzzi V., Bonaventura A., Mauro A.G., Cannat&#xe0; A., Pillappa R., Sinagra G., Nana-Sinkam P., Sime P., et al. Inflammasome formation in the lungs of patients with fatal COVID-19. Inflamm. Res. 2020;70:7&#x2013;10. doi: 10.1007/s00011-020-01413-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-020-01413-2</ArticleId><ArticleId IdType="pmc">PMC7572246</ArticleId><ArticleId IdType="pubmed">33079210</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenoy S. Coronavirus (Covid-19) sepsis: Revisiting mitochondrial dysfunction in pathogenesis, aging, inflammation, and mortality. Inflamm. Res. 2020;69:1077&#x2013;1085. doi: 10.1007/s00011-020-01389-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-020-01389-z</ArticleId><ArticleId IdType="pmc">PMC7410962</ArticleId><ArticleId IdType="pubmed">32767095</ArticleId></ArticleIdList></Reference><Reference><Citation>Manolis A.S., Manolis T.A., Manolis A.A., Papatheou D., Melita H. COVID-19 infection: Viral macro- and micro-vascular coagulopathy and thromboembolism/prophylactic and therapeutic management. J. Cardiovasc. Pharmacol. Ther. 2021;26:12&#x2013;24. doi: 10.1177/1074248420958973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1074248420958973</ArticleId><ArticleId IdType="pmc">PMC7492826</ArticleId><ArticleId IdType="pubmed">32924567</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng L., Li H., Li L., Liu C., Yan S., Chen H., Li Y. Ferritin in the coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J. Clin. Lab. Anal. 2020;34:e23618. doi: 10.1002/jcla.23618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcla.23618</ArticleId><ArticleId IdType="pmc">PMC7595919</ArticleId><ArticleId IdType="pubmed">33078400</ArticleId></ArticleIdList></Reference><Reference><Citation>Perricone C., Bartoloni E., Bursi R., Cafaro G., Guidelli G.M., Shoenfeld Y., Gerli R. COVID-19 as part of the hyperferritinemic syndromes: The role of iron depletion therapy. Immunol. Res. 2020;68:213&#x2013;224. doi: 10.1007/s12026-020-09145-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-020-09145-5</ArticleId><ArticleId IdType="pmc">PMC7366458</ArticleId><ArticleId IdType="pubmed">32681497</ArticleId></ArticleIdList></Reference><Reference><Citation>Sano M., Tamura T. Hydrogen gas therapy: From preclinical studies to clinical trials. Curr. Pharm. Des. 2021;27:650&#x2013;658. doi: 10.2174/1381612826666201221150857.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612826666201221150857</ArticleId><ArticleId IdType="pubmed">33349213</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Rao X., Li Y., Zhu Y., Liu F., Guo G., Luo G., Meng Z., De Backer D., Xiang H., et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann. Intensiv. Care. 2021;11:5. doi: 10.1186/s13613-020-00792-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-020-00792-3</ArticleId><ArticleId IdType="pmc">PMC7794643</ArticleId><ArticleId IdType="pubmed">33420963</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A., Czinn S.J., Reiter R.J., Blanchard T.G. Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19. Life Sci. 2020;255:117842. doi: 10.1016/j.lfs.2020.117842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117842</ArticleId><ArticleId IdType="pmc">PMC7245231</ArticleId><ArticleId IdType="pubmed">32454157</ArticleId></ArticleIdList></Reference><Reference><Citation>Sureda A., Alizadeh J., Nabavi S.F., Berindan-Neagoe I., Cismaru C.A., Jeandet P., &#x141;os M.J., Clementi E., Nabavi S.M., Ghavami S. Endoplasmic reticulum as a potential therapeutic target for COVID-19 infection management? Eur. J. Pharmacol. 2020;882:173288. doi: 10.1016/j.ejphar.2020.173288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173288</ArticleId><ArticleId IdType="pmc">PMC7297682</ArticleId><ArticleId IdType="pubmed">32561291</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller K., McGrath M.E., Hu Z., Ariannejad S., Weston S., Frieman M., Jackson W.T. Coronavirus interactions with the cellular autophagy machinery. Autophagy. 2020;16:2131&#x2013;2139. doi: 10.1080/15548627.2020.1817280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2020.1817280</ArticleId><ArticleId IdType="pmc">PMC7755319</ArticleId><ArticleId IdType="pubmed">32964796</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhri S., Nouri Z., Moradi S.Z., Akkol E.K., Piri S., Sobarzo-S&#xe1;nchez E., Farzaei M.H., Echeverr&#xed;a J. Targeting multiple signal transduction pathways of SARS-CoV-2: Approaches to COVID-19 therapeutic candidates. Molecules. 2021;26:2917. doi: 10.3390/molecules26102917.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26102917</ArticleId><ArticleId IdType="pmc">PMC8156180</ArticleId><ArticleId IdType="pubmed">34068970</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A., Pajares M., Benito C., Jim&#xe9;nez-Villegas J., Escoll M., Fern&#xe1;ndez-Gin&#xe9;s R., Garcia Yag&#xfc;e A.J., Lastra D., Manda G., Rojo A.I., et al. Can activation of NRF2 be a strategy against COVID-19? Trends Pharmacol. Sci. 2020;41:598&#x2013;610. doi: 10.1016/j.tips.2020.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2020.07.003</ArticleId><ArticleId IdType="pmc">PMC7359808</ArticleId><ArticleId IdType="pubmed">32711925</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousquet J., The ARIA Group. Cristol J.-P., Czarlewski W., Anto J.M., Martineau A., Haahtela T., Fonseca S.C., Iaccarino G., Blain H., et al. Nrf2-interacting nutrients and COVID-19: Time for research to develop adaptation strategies. Clin. Transl. Allergy. 2020;10:58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7711617</ArticleId><ArticleId IdType="pubmed">33292691</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang T., Harder B., de la Vega M.R., Wong P.K., Chapman E., Zhang D.D. p62 links autophagy and Nrf2 signaling. Free Radic. Biol. Med. 2015;88:199&#x2013;204. doi: 10.1016/j.freeradbiomed.2015.06.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2015.06.014</ArticleId><ArticleId IdType="pmc">PMC4628872</ArticleId><ArticleId IdType="pubmed">26117325</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosaka K., Mimura J., Itoh K., Satoh T., Shimojo Y., Kitajima C., Maruyama A., Yamamoto M., Shirasawa T. Role of Nrf2 and p62/ZIP in the neurite outgrowth by carnosic acid in PC12h cells. J. Biochem. 2010;147:73&#x2013;81. doi: 10.1093/jb/mvp149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jb/mvp149</ArticleId><ArticleId IdType="pubmed">19762340</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C., Cholevas C., Polyzoidis K., Politis A. Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. BioFactors. 2021;47:232&#x2013;241. doi: 10.1002/biof.1726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1726</ArticleId><ArticleId IdType="pmc">PMC8250989</ArticleId><ArticleId IdType="pubmed">33847020</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugon J., Msika E.-F., Queneau M., Farid K., Paquet C. Long COVID: Cognitive complaints (brain fog) and dysfunction of the cingulate cortex. J. Neurol. 2021;Jun 18:1&#x2013;3. doi: 10.1007/s00415-021-10655-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10655-x</ArticleId><ArticleId IdType="pmc">PMC8211714</ArticleId><ArticleId IdType="pubmed">34143277</ArticleId></ArticleIdList></Reference><Reference><Citation>Awogbindin I.O., Ben-Azu B., Olusola B.A., Akinluyi E.T., Adeniyi P.A., Di Paolo T., Tremblay M.&#xc8;. Microglial implications in SARS-CoV-2 infection and COVID-19: Lessons from viral RNA neurotropism and possible relevance to Parkinson&#x2019;s disease. Front. Cell Neurosci. 2021;15:670298. doi: 10.3389/fncel.2021.670298.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.670298</ArticleId><ArticleId IdType="pmc">PMC8240959</ArticleId><ArticleId IdType="pubmed">34211370</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Reyes A., Martinez-Armenta C., Espinosa-Vel&#xe1;zquez R., V&#xe1;zquez-C&#xe1;rdenas P., Cruz-Ramos M., Palacios-Gonzalez B., Gomez-Quiroz L.E., Mart&#xed;nez-Nava G.A. NLRP3 inflammasome: The stormy link between obesity and COVID-19. Front. Immunol. 2020;11:570251. doi: 10.3389/fimmu.2020.570251.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.570251</ArticleId><ArticleId IdType="pmc">PMC7662564</ArticleId><ArticleId IdType="pubmed">33193349</ArticleId></ArticleIdList></Reference><Reference><Citation>Mccarty M.F., Iloki Assanga S.B., Luj&#xe1;n L.L., O&#x2019;Keefe J.H., DiNicolantonio J.J. Nutraceutical strategies for suppressing NLRP3 inflammasome activation: Pertinence to the management of COVID-19 and beyond. Nutrients. 2020;13:47. doi: 10.3390/nu13010047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13010047</ArticleId><ArticleId IdType="pmc">PMC7823562</ArticleId><ArticleId IdType="pubmed">33375692</ArticleId></ArticleIdList></Reference><Reference><Citation>Mccord J.M., Hybertson B.M., Cota-Gomez A., Geraci K.P., Gao B. Nrf2 activator PB125&#xae; as a potential therapeutic agent against COVID-19. Antioxidants. 2020;9:518. doi: 10.3390/antiox9060518.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9060518</ArticleId><ArticleId IdType="pmc">PMC7346195</ArticleId><ArticleId IdType="pubmed">32545518</ArticleId></ArticleIdList></Reference><Reference><Citation>McCord J.M., Hybertson B.M., Cota-Gomez A., Gao B. Nrf2 activator PB125&#xae; as a carnosic acid-based therapeutic agent against respiratory viral diseases, including COVID-19. Free Radic. Biol Med. 2021;175:56&#x2013;64. doi: 10.1016/j.freeradbiomed.2021.05.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2021.05.033</ArticleId><ArticleId IdType="pmc">PMC8413148</ArticleId><ArticleId IdType="pubmed">34058321</ArticleId></ArticleIdList></Reference><Reference><Citation>Hybertson B.M., Gao B., Bose S., McCord J.M. Phytochemical combination PB125 activates the Nrf2 pathway and induces cellular protection against oxidative injury. Antioxidants. 2019;8:119. doi: 10.3390/antiox8050119.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox8050119</ArticleId><ArticleId IdType="pmc">PMC6563026</ArticleId><ArticleId IdType="pubmed">31058853</ArticleId></ArticleIdList></Reference><Reference><Citation>Della-Torre E., Criscuolo E., Lanzillotta M., Locatelli M., Clementi N., Mancini N., Dagna L., COVID-BioB Study Group IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19. Lancet Rheumatol. 2021;3:e829&#x2013;e831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8555969</ArticleId><ArticleId IdType="pubmed">34746843</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers T.F., Zhao F., Huang D., Beutler N., Burns A., He W.T., Limbo O., Smith C., Song G., Woehl J., et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369:956&#x2013;963. doi: 10.1126/science.abc7520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc7520</ArticleId><ArticleId IdType="pmc">PMC7299280</ArticleId><ArticleId IdType="pubmed">32540903</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Okbi S.Y. Nutraceuticals of anti-inflammatory activity as complementary therapy for rheumatoid arthritis. Toxicol. Ind. Heal. 2012;30:738&#x2013;749. doi: 10.1177/0748233712462468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0748233712462468</ArticleId><ArticleId IdType="pubmed">23104728</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukaczer D., Darland G., Tripp M., Liska D.A., Lerman R.H., Schiltz B., Bland J.S. A Pilot trial evaluating meta050, a proprietary combination of reduced iso-alpha acids, rosemary extract and oleanolic acid in patients with arthritis and fibromyalgia. Phytother. Res. 2005;19:864&#x2013;869. doi: 10.1002/ptr.1709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ptr.1709</ArticleId><ArticleId IdType="pubmed">16261517</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>